<DOC>
	<DOCNO>NCT03089099</DOCNO>
	<brief_summary>As prostate cancer progress castration-resistant stage initial hormone-sensitive status , biological behavior tumor cell dissociate primary lesion change . Considered `` liquid biopsy , '' circulate tumor cell ( CTCs ) show patient 's cancer respond treatment . The purpose study determine whether sequentially analyze expression molecular marker high volume circulate tumor cell metastatic castration-resistant prostate cancer patient predict therapeutic effect outcomes patient .</brief_summary>
	<brief_title>Expression Molecular Markers Circulating Tumor Cells Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>1 . Male patient 2 . 18 yrs old , 80 yr young 3 . Histologically cytologically proven prostate adenocarcinoma ; 4 . Imaging examination include Emission Computed Tomography ( ECT ) , Positron Emission Tomography ( PET ) reveal highvolume disease patient ( A highvolume disease define presence visceral metastasis four bone lesion least one beyond vertebral body pelvis ) 5 . Have receive hormonal therapy progress castrationresistant stage 6 . Not yet receive chemotherapy 7 . Patients willing participate follow regularly 1 . Received treatment abiraterone acetate previously 2 . Patients receive chemotherapy previously 3 . Combined malignant tumor history ( addition skin basal cell carcinoma tumor cure five year ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic Castration-Resistant Prostate Cancer</keyword>
	<keyword>circulate tumor cell</keyword>
	<keyword>Prognosis</keyword>
	<keyword>Liquid biopsy</keyword>
</DOC>